甲基斑蝥胺(Methylcantharidimide) - 在研适应症：肝癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Methyl cantharidimide、甲基斑蝥二胺片、甲基斑蝥胺

靶点-

作用机制-

治疗领域

肿瘤消化系统疾病

在研适应症

肝癌

非在研适应症-

原研机构

在研机构

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (1990-01-01),

肝癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C11H15NO3

InChIKeyWUQNOBSCYAIJIH-FIPCFZRWSA-N

CAS号76970-78-0

关联

1

项与甲基斑蝥胺相关的临床试验

NCT03996681 / Unknown status临床4期IIT

A Prospective Clinical Trial of TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma

The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with methylcantharidimide tablets in the treatment of patients with large and unresectable hepatocellular carcinoma.

开始日期2019-07-20

申办/合作机构-

100 项与甲基斑蝥胺相关的临床结果

登录后查看更多信息

100 项与甲基斑蝥胺相关的转化医学

登录后查看更多信息

100 项与甲基斑蝥胺相关的专利（医药）

登录后查看更多信息

10

项与甲基斑蝥胺相关的文献（医药）

2014-11-15·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

Effects of methyl cantharidimide tablets on urinary protein and enzymes in Beagle dogs

Article

作者: Hu, Rong ; Yang, Xue ; Deng, Jian-yi ; Tu, Ru-xia ; Lan, Bo ; Luo, Xian-qin ; Huang, Wen-tao

OBJECTIVE:

To investigate the nephrotoxic effects of methyl cantharidimide tablets on urinary protein and enzymes in Beagle dogs.

METHOD:

Beagle dogs were randomly divided into negative control group(blank tablet), methyl cantharidimide tablets group (6.11,12.21, 24.42 mg x kg(-1)), continuously 30 days of oral adminiStration, once a day. The drug and control group were collected and determined fresh urine in 1, 2, 3 and 4 weeks of the administration; Serum urea nitrogen (BUN), creatinine (Crea), total protein (TP) and albumin (ALB) as well as sodium, potassium, chloride electrolyte were determined on 15 and 30 days of the administration; Urine albumin (mAlb), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin( NGAL), N-acetyl-beta-D-glucosaminidase (NAG), clusterin, beta2-microglobulin (beta2-MG), alpha1-microglobulin (alpha1-MG), alanine aminopeptidase( AAP) and im- munoglobulins IgG were tested on 15 and 30 days of the administration.

RESULT:

Compared with the control group, urine protein and white blood cells was significantly increased in each dose group. On 15 days of the administration, mAlb were higher in each dose group, KIM-1, NGAL, clusterin, NAG and AAP were significantly higher in high-dose group, while the middle and low dose group had no significant difference, as well as blood SCr and BUN no obvious abnormalities. On 30 days, mAlb, KIM-1, clusterin, NAG, AAP were increased in each dose group, appearing dose-effect relationship, beta2-MG and NGAL levels were significantly increased in high-dose group. Contents above indicators were increased with significant dose and time relationship, and serum BUN, Scr were correlated, suggesting that urine mAlb, KIM-1, clusterin, NAG and AAP indicators that can sensitively respond the changes of proteins and enzymes in urine.

CONCLUSION:

Methyl cantharidimide tablets has a renal toxicity, urine mAlb, KIM-1, clusterin, NAG and AAP can be used as the early nephrotoxic biomarkers of methyl cantharidimide tablets.

2013-11-01·Chemical biology & drug design4区 · 医学

Cantharidin‐Based Small Molecules as Potential Therapeutic Agents

4区 · 医学

Review

作者: Vargas Méndez, Leonor Y. ; Puerto Galvis, Carlos E. ; Kouznetsov, Vladimir V.

Chemical and pharmacological information on cantharidin‐based small molecules was analyzed. The review summarizes new facts about blister beetles' metabolites for the period 2006–2012. General synthetic approaches to cantharidin‐based small molecules as well as their chemical transformations and biological activities related to cantharidin, norcantharidin, cantharidimide, and norcantharimide analogs, especially their inhibitory activity of phosphoprotein phosphatases in cancer treatment, were discussed in this mini review, which could help to design new small molecule modulators for other biological models.

2010-10-01·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

Determination of plasma concentration of N-methylcantharidimide by HPLC and its pharmacokinetics after intravenous administration in dogs

Article

作者: Xiaobo Wu ; Xianqin Luo

OBJECTIVES:

To establish a HPLC method for determination of N-methylcantharidimide in dogs' plasma and to study the pharmacokinetics of N-methylcantharidimide in dogs'.

METHOD:

The plasma samples were extracted by methanol. The acetonitrile and the purified water composed mobile phase. The flow rate was 0. 7 mL x min(-1), ultraviolet detection wavelength was at 212 nm.

RESULT:

The calibration curve was linear over the range from 0.01-10.0 mg x L(-1) with a correlation coefficiency of 0.996 3. The lower limit of quantitation was 0.01 mg x L(-1). The mean recovery was 92.3%. the relative standard deviation (RSD) of intra-day and inter-day were all less than 10%. After intravenous administration of N-methylcantharidimide with 3 dosages of 10, 15, 20 mg x kg(-1) to dogs, the corresponding distribution half-livers (t1/2alpha) were 1.8, 2.1, 1.7 min, and the elimination half-lives (t1/2beta) were 144,139, 146 min, respectively.

CONCLUSION:

This method is convenient, accurate and reliable. It can be used for determination of N-methylcantharidimide in dogs' plasma and pharmacokinetic studies.

100 项与甲基斑蝥胺相关的药物交易

登录后查看更多信息